Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;35(5):343-6.
doi: 10.5581/1516-8484.20130099.

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation

Alberto Olaya Vargas  1 , Roberto Rivera Luna, Martin Perez Garcia, Rocio Cárdenas Cardos, Liliana Velasco Hidalgo, Doris Lordméndez Jácome, Mariana Campos Gutiérrez
Affiliations

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation

Alberto Olaya Vargas et al. Rev Bras Hematol Hemoter. 2013.

Abstract

Background: In childhood cancer, consolidation treatment with chemotherapy followed by autologous hematopoietic progenitor stem cell transplantation is currently an accepted treatment modality in patients with high-risk solid tumors or in patients who have relapsed after conventional treatment.

Objectives: The objective of this study was to describe the results of transplantation of a group of children who had high-risk solid tumors or relapsed after conventional chemotherapy regimens.

Methods: A retrospective analysis was conducted from January 1998 to October 2004 of all children with pathologic diagnoses of high-risk solid tumors or children that had previously relapsed after conventional chemotherapy and that were subsequently submitted to autologous hematopoietic progenitor stem cell transplantation. The analysis included overall survival rates, event-free survival rates, mortality rates and chemotherapy complications.

Results: Nineteen patients were submitted to this approach. The age range was from 27 to 196 months with a median age of 52 months. The overall survival rate at 100 days was observed in 79%, the three-year event-free survival rate was 63%. The mortality rate secondary to the myeloablative chemotherapy regimen was 21% (n = 4). Only three patients (15.8%) relapsed with tumor progression after transplant.

Conclusion: Autologous hematopoietic progenitor stem cell transplantation is still a successful procedure in patients with solid tumors refractory to conventional chemotherapy.

Keywords: Child; Hematopoietic stem cell transplantation; Neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest

Figures

Figure 1
Figure 1
Event-free survival of 19 pediatric patients with high-risk solid tumors conditioned with melphalan, cyclophosphamide and etoposide and autologous hematopoietic progenitor stem cell transplantation
Figure 2
Figure 2
Event-free survival by tumor type in 19 pediatric patients conditioned with melphalan, cyclophosphamide and etoposide and autologous hematopoietic progenitor stem cell transplantation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ozkaynak MF, Sahdev I, Gross TG, Levine JE, Cheerva AC, Richards MK, et al. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. J Pediatr Hematol Oncol. 2008;30(3):204–209. - PubMed
    1. Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, et al. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant. 2006;37(7):661–668. - PubMed
    1. Shook DR, Triplett BM, Srinivasan A, Hartford C, Dallas MH, Pillai A, et al. Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant. 2013;19(2):291–297. - PMC - PubMed
    1. Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors -Bulgarian experience. J BUON. 2006;11(4):433–438. - PubMed
    1. Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, et al. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant. 2006;37(7):661–668. - PubMed

LinkOut - more resources